Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

Elucidating the Mechanistic Insights and Therapeutic Potential of Targeting Thioredoxinreductaseinredox-Regulated Anticancer Drug Development

Muhammad Shahbaz

Department of Zoology, Women University, Azad Kashmir, Bagh

Anum Sadiq

Department of Zoology,Women University Azad Jammu and Kashmir, Bagh

Syeda Najaf

Department of Zoology ,Women University oAzad Jammu and Kashmir ,Bagh

Tabinda Iftikhar

Department of Zoology,Women University of Azad Jammu and Kashmir,Bagh

Shazia Nazir

Live Stock and Dairy Department of AJK

Zakia Arif

Department of Zoology,Women University of Azad Jammu and Kashmir, Bagh

Hasina Arif

Department of Zoology,Women University of Bagh Azad Jammu and Kashmir

Samira Gulzar

Department of Zoology ,Women university of azad Jammu and Kashmir

Ayesha Azad

Department of Zoology,Women University of Bagh Azad Jammu and Kashmir

Noor Un Nisa

Department of Eastern Medicine Government College University Faisalabad

Muhammad Akram*

Department of Eastern Medicine Government College University, Faisalabad. Corresponding Author Email: muhammadakram@gcuf.edu.pk

Ghulam Abbas

Department of Eastern Medicine, University of Poonch Rawalakot Azad Kashmir, Pakistan

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

ABSTRACT

The fear of cancer is what definitely causes the highest death rates of the patients and the global statistics. Cancer is a result of the very rapid cell division Process which, in turn, generates an excessive number of abnormal cells, the precursors of the tumors, which are the main reason for the death of not only the tissues near but also the tissues surrounding them. The genetic alterations leading to the growth of a tumor are many and they are of different origins. These mutations take control over the normal signaling pathways that were meant to regulate the growth and demise of the tissue within the organism obscuring the balance that was already tilted towards death. The cancer storm has started to reveal its profoundly negative impacts on both the individual and the whole society. A huge number of people with cancer continue to be diagnosed every year which clearly shows that social position, location, and race are among the determinants of the disease occurrence within a certain population. The oncogenic mutation has caused a transformation in the gene of cancer's core wherein the gene has 'lost' control over the cell cycle by activating the process of cell division and, at the same time, differentiating and, ultimately, killing the cells. Should we accept Hanahan and Weinberg's definition, the features of cancer like immortal (not dying), limitless cell division, immune system evasion, etc., were presented as blood supply formation and metastasis (transfer to other organs) and changing of the tumor's metabolism. These features continue to represent the main focus of research and the development of new treatments in the cancer area. Among the various factors contributing to the cancer process, oxidative stress has been recognized as the most important one.

INTRODUCTION

Introduction to Cancer Biology

Overview of Cancer

Cancer is a pathological condition that can disrupt the normal regulation and control of cells through metabolism. Tumor cells are the antagonists in this scenario since they are the ones that rapidly divide and spread to healthy tissues, thus causing the

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

latter to die. Furthermore, the disease has been taking lives and has been killing people, thus it has been recognized as one of the worst health issues on earth. Various types of cancer exist but they all have one thing in common, which is the alteration of the genetic material of the cancer-affected cells. Gene mutations can be either passed down from parent to child or occur as a result of aging. In either case, the normal cell function is disrupted and as a consequence, the organism gets sick and eventually diseases occur. Cancer has been a significant problem not only to the patients affected but also to society as a whole. The latter has to bear the burden of this calamity. It still remains the major health care issue that comes into the domain of humanity as imparting unbearable pain and leading to the death of millions annually, thus being regarded as one of the most serious global health problems. The chance of getting cancer is a random one and is affected by many factors such as age, sex, race, place of living, and wealth. To simplify, cancer might be labeled as a genetic switch that uncovers the cell's capabilities of proliferating, maturing, and dying. The modifications in the genes may be of either kind, that is, inherited or acquired. Consequently, this results in the emergence of a bunch of cells that are unruly and wild, like not abiding by the "laws" that the other cells obey, thus becoming "dangerous". In the year 2000, the researchers Hanahan and Weinberg reached a significant turning point by publishing their paper where they identified the six fundamental characteristics that almost all cancer cells share.

The intercellular connections in tumors are established as a result of a cellular signaling which is the same signal that causes the overall division and growth of the cells. Besides, the tumor cells refuse to accept the killing signals that are intended to either arrest the cell cycle or kill the cell by apoptosis. One of the benefits of living longer for cancer cells is that the process which eventually leads to their death or even quicker growth in unfavorable conditions is still going on. They are able to keep their telomeres and also pass through that aging stage which generally halts cell division, thereby becoming immortal and being able to grow indefinitely (Witch E et al., 2010). Tumors increase blood supply by new vessels to meet their heightened demand for oxygen and nutrients (Carmeliet P et al., 2000). Tumor cells can invade the surrounding tissues and then migrate to far distant

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

locations in the body where they will establish new tumors (Steeg PS et al., 2006). The rapid and healthy growth of cancerous cells is accompanied by a metabolic shift in the case of energy production. Furthermore, cancerous cells are saying that the immunological shields have made them invincible and thus allowed them to multiply without any constraints. The cancer consists of multiple cell types with one type residing within the tumor and another in the surrounding area. The genes of the tumor cells, epigenetic factors, and the physical traits that differentiate the cells and the tumor are all involved in the different behaviors of the tumor, varied responses, and resistances to treatment and different health impacts. Additionally, cancer cells repeatedly change during their lifetime, and thus they acquire new genetic mutations that speed up disease progression and render treatment ineffective.

Role of Oxidative Stress in Cancer Biology

Oxidative stress can be defined as the imbalance between the excessive generations of a group of toxins called reactive oxygen species (ROS) in the human body and the inadequate removal of these toxins. A cell's death is due to the non-functioning of its active part and damage done to proteins, fats, and DNA that are unable to be formed correctly. This situation is typical for aging and may even lead to cell death that cannot be reversed. The body produces ROS at a normal rate, which is a natural metabolic process, with the main sites being mitochondria, peroxisomes, and certain enzymes including NADPH oxidase and nitric oxide synthase. Among the different types of ROS are superoxide radicals, hydrogen peroxide, and hydroxyl radicals. Oxidative stress has been associated with and even blamed for the progression of many diseases, including cancer. In the diagnosis of oxidative stress in various diseases, the presence of biomolecules such as the above-mentioned antioxidative proteins and 8-hydroxy-2-deoxyguanosine (8-OHdG), among others, is a prerequisite. The study of Malondialdehyde (MDA), a product of lipids peroxidation, is another example of the solid link between oxidative stress and diseases. The current research has mainly focused on the impact of oxidative stress in different cancer types - breast, prostate, lung, colon, cervical, ovarian, brain, bladder, kidney, thyroid, and chronic lymphocytic leukemia. The data support the theory that a cancer patient has a lower level of antioxidants, on the one hand, and a higher level

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

of oxidative stress markers, such as MDA and 8-OHdG, on the other hand, thus suggesting an active oxidative process in these patients.

Sources of Oxidative Stress

Oxidative stress, the creation of reactive oxygen species (ROS), and other similar phenomena are caused by a number of factors, both internal and external, such as: Metabolism: Superoxide radicals can be produced during oxidative phosphorylation in mitochondria due to the accidental leakage of some electrons from the electron transport chain. Inflammation: The immune response in the areas of the infected tissues causes the production of ROS and those areas may also be suffering from oxidative stress. Environmental factors: The aforementioned pollutants, cigarette smoke, radiation, and chemicals are included in the list of environmental factors that impose heavy demands on the cellular antioxidant systems leading to the vast production of ROS. Redox signaling: The recognition that ROS has a key role in the regulation of important cellular processes such as apoptosis, differentiation, etc. is already widespread.

Oxidative Stress and the Start of Cancer

High levels of oxidative stress can lead to the oxidative damage of the whole cell, including the lipids, proteins, and nucleic acids, thus impairing cell functions. However, one of the possible direct consequences of continuous oxidative stress on DNA is that it can cause mutations. In this way, such mutations could change the usual process of cancer cell proliferation through the gene activities that either promote or resist tumor growth, thus by the factors of cell birth and natural death or division timing. In addition, genetic instability is a common feature of cancer which could be, according to the study done by Abreu IA et al. and published in 2010, the outcome of DNA damage to reactive oxygen species (ROS).

Antioxidant Defense Systems' Function

The body's first line of defense is always, its own antioxidant systems, formed by cells. These antioxidant defense systems neutralize the reactive oxygen species (ROS) that the body constantly produces and manages the chemical balance of the body. The big three of the antioxidant enzymes group are glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase. These enzymes transform reactive

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

oxygen species into less harmful substances. The non-enzymatic antioxidants such as GSH, vitamin C and E, and flavonoids are also involved in the scenario as they not only help the cells indirectly but also enable the cells to coexist with the attackers since the attackers do not have direct confrontation with the cells through these indirect helpers. Oxidative stress—the gatekeeper of tumor formation: A certain range of ROS production which is from low to moderate is a must for cells to operate and communicate with each other. But, the long-lasting process which is mentioned above may metamorphose one of the paths into the cancer route: Heightened cell multiplication: The presence of ROS may lead to the activation of the PI3K/Akt and MAPK pathways which are responsible for cell growth and survival.DNA alterations: One of the negative consequences of ROS on DNA is that they cause mutations and lead to genetic instability which not only facilitates tumor development but also contributes to the diversity of the tumor.

Redox Homeostasis

Redox homeostasis is a phrase that denotes a state that can either somewhat be described as “the cell’s life-support system” or “the operating cell condition” inside the cell resulting from very close to not really being able to live oxidation and reduction reactions depending on the cell. Predominantly, this state is maintained through the battle between the antioxidants and the oxidants like the reactive oxygen species, which are not only the main source of the oxidants in the cell's surroundings but also the most abundant ones. In a nutshell, oxidation and reduction mean simply electron transfer, involving one molecule giving and another receiving the electrons.

Besides, these reactions are humans’ main ones, and their advantages among others are energy production, molecular synthesis and inter-cellular communication. Reactive alone, however, is a one-sided view of the situation, since the term reactive oxygen species (ROS) comprises not only superoxide anions, hydrogen peroxide and hydroxyl radicals. The most dominant generating activity is energy-consuming metabolism, physiological stress and inflammation. Their presence during cell cycle is considered normal though an overload may lead to cell death. But at the same time, the cells are packed with strong defenses, which not only eradicate the total

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

oxidative stress but also keep the redox balance in place. The three main antioxidant enzymes namely glutathione peroxidase, catalase and superoxide dismutase are an integral part of these defense strategies. SOD converts superoxide anions into hydrogen peroxide, which is then further broken down either by catalase or GPx. In addition, the roles of non-enzymatic antioxidants like flavonoids, vitamins C and E, and glutathione are primarily to the detoxification of the ROS or to assisting others in achieving this aim. Generally, redox signaling is considered to be the application of molecules with various oxidation states to control a multitude of bioproces Redox

Homeostasis Dysregulation in Cancer

The development of tumor cells causes a considerable alteration in the body's redox state which can subsequently lead to either the tumor's enlargement or its dispersion. By exploiting their leaky metabolism, tumor cells typically discharge huge quantities of ROS day and night. This overproduction might be partially due to impairments in cellular signaling which affect mitochondrial function producing oxidative stress and all these are viewed as metabolic states. It is highly likely that the utilization of antioxidants by cancer cells is not the same. The scenario in which healthy cells die due to the oxidative stress caused by the failure of the protective enzymes is that the tumor cells would continue their growth. On the other hand, the redox alteration could also be a means to indirectly control some signaling pathways thus causing the cell to lose its regulation. For instance, the PI3K/Akt and NF-κB pathways, which provide cancer cells with the ability to survive, proliferate, deregulate the blood supply, and metastasize, might be turned on.

Therapeutic Targeting of Redox Homeostasis

Redox homeostasis can be therapeutically targeted through treating cancer, for instance. The application of antioxidant therapies, which diminish the cell's treatment resistance, is one of the methods that have reversed the situation by lowering oxidative stress. This can be done through enhancement of the body's antioxidant defenses or by providing the patient with external antioxidants. The third method applies agents that cause oxidative stress. The agents lead tumor cells to pump more ROS and finally cause them to die, thus, the tumor's growth is restricted. The approach of using a combination of ROS-producing drugs and

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

traditional cancer therapy is one that will most probably be thoroughly examined. It not only guarantees that the treatment will be more effective but also that the resistance will be lost. Thioredoxin system: overview and purpose The Thioredoxin is a protein of small size that enables the cells to endure oxidative stress, which is a process that involves swapping pairs of cytokine thiols for disulfides. The gTrxR, which has a selenium atom in its structure, is the enzyme responsible for thioredoxin activation and thus it is able to perform redox reactions. The involvement of thioredoxin in gene regulation, apoptosis, and cell division is among the many processes. The thioredoxin system leads these processes by signaling through redox. Biochemical Understanding of Thioredoxin Reductase TrxR is a promoter of the reducing process of thioredoxin and also that of other materials by means of chemical reactions. This is an important step for maintaining the redox balance in cells. Heaven and earth factors control the activities of TrxR that produce the quantity of TrxR and its effectiveness in normal and cancer cells.

Redox Regulation in Cancer

Reactive oxygen species (ROS) are a hallmark of cancer cells because of their elevated metabolic rates, fast growth, and changed redox environment. Cancer cells primarily depend on antioxidant mechanisms, such as the Trx system, to withstand oxidative stress. Since of this reliance, TrxR is a desirable target for anticancer treatment.

Reactive oxygen species (ROS), which contribute to aging and the enhancement of cellular defense mechanisms, have long been linked to cancer growth. (Valko, M et al., 2006). Cancer cells have higher ROS levels, which contribute to genetic instability and tumor development (Trachootham, D et al., 2009). Paradoxically, cancer cells have increased antioxidant capability, which helps them survive in the tumor microenvironment.

New TrxR inhibitors with great therapeutic potential have been developed as a result of recent developments inourknowledg eof the molecular mechanisms controlling TrxRand its function in cancer. These inhibitors push the redox balance towards cell death without substantially impacting normal cells by taking advantage of the increased oxidative stress in cancer cells. The fact that TrxR is involved in

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

drug resistance processes further emphasizes the therapeutic potential of targeting it, and TrxR inhibitors are useful in treating resistance to traditional chemotherapy. We can better appreciate the promise of TrxR inhibitors in the ongoing search for efficient cancer therapies by knowing the crucial role that TrxR plays in cancer cell survival and resistance.

Redox Regulation in Cancer

It is certainly known that redox signals participate in the hallmarks of virtually all diseases (Hornsveld M et al., 2016). Redox flagging pathways, which are regulated by catalysts such as TrxR, influence key cell cycle processes such as proliferation, apoptosis, and angiogenesis. It cannot be expected, then, that the Trx framework, one of the focal agents of cell redox guideline organization, participates in disease amelioration. Accordingly, framework over expression is normal in cancer cells. Certainly, the Trx framework may play a dual role in progression events, improvement, and proliferation with disease stage. At early stages; this framework's rapid cell reinforcement capability may protect normal cells from the dangerous changes caused by xenobiotic oxidative stress (Schumacher PT et al., 2006; Arner ESJ et al., 2006). A low degree of Trx may cause a variety of disease events and motions due to the dysregulation between cell reinforcement framework and oxidative stress (Tonissen KF et al., 2007). Superoxide (O2-), hydrogen peroxide (H2O2), and hydroxyl radicals (Gdni) are synthetic reactive oxygen species produced from atomic oxygen (C.I.Kobayashi et al., 2012). Malignantly developing cells exhibit dysregulated redox balance, characterized by enhanced levels of reactive oxygen species (ROS) (Giannoni et al., 2005). Dysregulation of TrxR has been implicated in various diseases, increasing cancer growth, metastasis and protection against chemotherapy. TrxR overactivation/breakdown has been linked to the management of various diseases, particularly cancer. Most disease cells have increased expression of TrxR and Trx, and this overexpression is expected to exhibit characteristics of malignant growth cells, such as increased rates of DNA synthesis, inhibition of anticancer agents, and cell proliferation (Arner ESJ et al., 2009).

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

Structure and Function of Trx and TrxR

The human thioredoxin (Trx) framework, one of the essential frame works for maintaining redox regulation in cells, consists of the seleno protein thioredoxin reductase (TrxR), the minor broad redox protein Trx, and the reducing substrate NADPH. Sec buildup is detected near the cysteine (Cys) at the C-terminus of the protein. The C- terminal redox-dynamic center of TrxR contains both Sec and Cys (Zhong Let al., 2000). (Zhang J et al., 2021).

The three-layered state of E. coli Trx changed to the description by Holmgren et al. in the 1970s to a target of 2.8A˚, and all Trx proteins have a common conformation, consisting of 4a-helicesand 5 b-sheets. The highly monitored dynamic site Most malignant growth cells have increased expression of TrxR and Trx, and this over expression is expected to coexist with disease cell aggregates such as accelerated DNA synthesis, cancer prevention, etc. The agent limits up-regulation, promotes cell growth, and protects against apoptosis (Dixit D et al., 2018).

TrxR chemicals are additionally important parts of the Trx framework. TrxRs are grouped into two categories, low molecular weight (MW) TrxRs (35 kDa each) with less organisms (microorganisms, archaea, plants, and most unicellular eukaryotes) and high MW TrxRs with transcriptional guidelines. , which together decide cell multiplication. Death is not really that the frustration of this framework is linked to different diseases. In addition, the Trx framework is important in cell redox signaling because it directs the movement of several transcription factors. (Lillig CH et al., 2007).

TrxR Inhibitors

TXNIP (thioredoxin cooperating protein) is an endogenous Trx inhibitor (Yoshioka J et al., 2006). Allicin's truly active ingredient is dialysyl trisulfide, a characteristic organosulfur compound derived from garlic that has been used as a therapeutic agent since ancient times. Various studies have found that dialysate trisulfide can inhibit the growth of disease cells in vivo, including bosom malignant growth. Lu and collaborators, suppresses metastasis of triple-negative Bosom disease (TNBC) by targeting the Trx framework (Liu Y et al., 2018).

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

Yin and collaborators identified several regular diterpenoids isolated from Jatropha integerrima as TrxR inhibitors, with IC50 values ranging from 6.8 to 39.1 lM (Zhu J-Y et al., 2015). Trx is a cell-based oxidative stress marker. In patients with rheumatoid arthritis (RA), Trx expression was increased primarily in stimulated joint synovial fluid and serum. DNA synthesis, threatened cells require higher levels of the thioredoxin framework. Several clinical drugs have been reported to inhibit TrxR at the transduction level (Witte Stomach muscle et al. ., 2005). The absence of clear TrxR inhibitors is a significant obstacle to the development of an effective TrxR inhibitor as a therapeutic agent. Sulfhydryl cluster has a comparable but moderately weaker reactivity than the silenol cluster. Because cells contain very high critical levels of thiols, it is difficult for these inhibitors to avoid cross-reaction with thiols. Since catalysis is highly dependent on Cys residues, it is fundamental to find moieties that can replace them. TrxR is markedly inhibited without affecting different catalysis. Physiological conditions, selenolate, a prevalent type of Sec selenol cluster, are almost a significant degree more nucleophilic than Cys thiolate (Reich HJ et al., 2016).

Becker et al. Unraveled the design nuances of the late human TrxR1-Trx1 complex as well as the Plasmodium falciparum TrxR-Trx complex (Fritz-Wolf K et al., 2013). Construction of human TrxR1-Trx1 complex hTrx1 31-74 and hTrxR1 plus 103-146, such as W31hTrx1-W'114, K36-E'103, D60-R'6617, D60-117, and D60-146 is determined. E70-R'121, and K72-E'122 (letters with a best represent hTrxR1) (Fritz-Wolf K et al., 2011).

Natural Molecules Targeting Thioredoxin System

TrxRs are regulated by the Nrf2-ARE flagging pathway, and TrxRs are key proteins for cell neuroprotection as shown by research (CebulaMetal. 2015). We screened and further modified active compounds in useful food sources and Chinese herbal medicine and found that several compounds can activate Nrf2 and regulate downstream cell robustness properties, including Trx and TrxR, PC12. These substances include 6-dehydrogingerdione, 6- shogaol, xanthohumol and its ana-logs, hydroxytyrosol, analogs of piperlongumine, cardamom, honokiol, mangiferin, costunolide, chlorogeniccorrosive, and lipoamide. They have incredible protection

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

against H2O2 or 6-OHDA-induced PC12 cell damage. These compounds can translocate Nrf2 to the nucleus, where it can then activate Nrf2-activated cell reinforcement particles such as hemeoxygenase-1, NAD (P) Hquinonedehydrogenase 1, glutathione (GSH), Trx, and TrxR. In addition, Amedi and colleagues announced that quercetin can reduce H2O2-induced apoptosis and ROS generation. Activation of Trx and TrxR is fundamental to the neuroprotective effect of these molecules. Regulated particles, by implementing the Trx framework, also play an important role in malignant growth chemoprevention (CosteaTetal. 2018). Nakamura and colleagues found that 14 drugs can increase hepatic Trx and TrxR protein levels while simultaneously increasing Nrf2 activity (KaimulAMetal. 2007; Jakubikova J et al., 2006). Allison's dynamic fixing, dialysal disulfide, is apromising chemopreventive agent. It has been calculated that a fraction of A549 cells treated with 20 can prolong the TrxR process. Streptomyces parvulus produced manumycin A, a characteristic inhibitor of farnesyl transferase. Yeung and colleagues revealed that mannomycin An induced apoptosis in anaplastic thyroid disease cells (ARO and AKT4) by regulating the redox state (She M etal. 2006). At this point, when ARO and AKT4 cell lines are treated with manumycin A, the intracellular GSH level drops substantially and ROS levels increase, leading to oxidative stress. Sen and colleagues similarly found that manumycin A can induce glioma cell apoptosis by increasing ROS levels (Dixit et al., 2009).

Future Perspectives and Clinical Implications

The identification of natural compounds as specific Thioredoxin Reductase (TrxR) inhibitors presents promising future prospects for precision cancer therapy. Further research should focus on personalized treatment strategies based on the redox status of individual tumors, exploring combinatorial approaches with existing anticancer drugs, and establishing reliable biomarkers for patient stratification. The clinical implications are significant, potentially leading to a new class of targeted anticancer therapies with improved overall treatment outcomes, reduced chemotherapy resistance, and enhanced patientsurvival. The specificity of natural TrxR inhibitors may minimize treatment-related side effects, offering a more tolerable therapeutic approach that could revolutionize cancer treatment in the clinical setting.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

Materials

1. Cell Lines

- Cancer cell lines: A549 (lung carcinoma), MCF-7 (breast carcinoma), HCT116 (colon carcinoma).
- Normal cell lines: MCF-10A (non-tumorigenic epithelial cell line), WI-38 (human fibroblasts).

Reagents

• Antibodies for Western blotting (anti-thioredoxin reductase, anti-PARP, anti-caspase-3, anti-β-actin).

• Apoptosis detection kits (Annexin V-FITC/PI).

• Cell viability assays (MTT, Cell Titer-Glo).

• Thioredoxin reductase inhibitors (e.g., Auranofin, D9-THX).

• ROS/RNS detection reagents (e.g., DCFDA for ROS, DAF-FMDA for RNS).

• Antioxidants (e.g., N-acetylcysteine, glutathione).

• Cell culture media (DMEM, RPMI-1640, supplemented with 10% FBS and 1% penicillin-streptomycin).

• siRNA/hsRNA for thioredoxin reductase inhibition.

• Plasmids for thioredoxin reductase overexpression.

Instruments

• Flow cytometer.

• Fluorescence microscope.

• Plate reader.

• Western blot equipment.

• qPCR machine

METHODOLOGY

In vitro studies

Cell Culture:

• Healthy and cancerous cells were maintained in appropriate culture medium at 37 °C with 5% CO2 in the air.

• Cells were subcultured to 70–80% confluence.

. Thioredoxin reductase inhibition:

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

• Cancerous and normal cell lines were treated with different concentrations of thioredoxin reductase inhibitors (e.g., auranophine) for various periods (24, 48, and 72 hours).

• Vehicle-treated control groups (DMSO) were included.

siRNA/shRNAKnockdown:

Cancer cells were transfected with siRNA/hsRNA targeting thioredoxin reductase using a suitable transfection reagent.

1. A coded siRNA/hsRNA control was included.

Inhibition efficiency was assessed by qPCR and Western blot.

2. Overexpression studies:

Cells were transfected with plasmids encoding thioredoxin reductase.

Transfection with an empty vector was included as a control.

Overexpression was confirmed by qPCR and Western blot.

Cell viability assays:

Cell viability was assessed post-treatment using MTT or CellTiter-Glo assays, according to the manufacturer's protocol.

Results were normalized to control groups, and IC50 values were determined for the inhibitors.

ROS/RNS measurement:

Cells were treated with ROS/RNS detection reagents (e.g., DCFDA for ROS, DAF-FM DA for RNS).

Intensity was measured using a fluorescence microscope or a plate reader.

Apoptosis assays:

Annexin V-FITC/PI staining was performed to detect apoptosis by flow cytometry.

Apoptotic markers were confirmed by Western blot for cleaved PARP and caspase-3.

• Collect cells and prepare protein lysates.

• Separate the proteins using SDS-PAGE and transfer them to PVDF membranes.

• Scan with specific primary antibodies (anti-thioredoxin reductase, anti-PARP, anti-caspase-3, anti-β-actin) followed by secondary antibodies conjugated to HRP.

• Visualize the bands using chemiluminescence.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

Collect cells and prepare protein lysates.

Separate the proteins using SDS-PAGE and transfer them to PVDF membranes.

Scan with specific primary antibodies (anti-thioredoxin reductase, anti-PARP, anti-caspase-3, anti-β-actin) followed by secondary antibodies conjugated to HRP.

Visualize the bands using chemiluminescence.

QuantitativeReal-TimePCR(qPCR):

- RNAwasextractedfrom treatedandcontrolcells usinganRNA extractionkit.
- SynthesizecDNAusingreverse transcriptase.
- qPCRwasperformedwithspecificprimersforthioredoxinreductaseand housekeeping genes (e.g., GAPDH).
- Geneexpressionchanges relativetocontrol groupswasanalyzed.

2. StatisticalAnalysis:

- Statisticalanalysiswasperformedbyusingsoftware(e.g.,GraphPadPrism).
- Appropriatetestswasused(e.g.,Student'st-test,ANOVA)todetermine significance.
- Presentdataasmean ±SDand considerp <0.05asstatisticallysignificant.

InVivoStudies

1. AnimalModels:

- Immunocompromisedmicewasused(e.g.,NOD/SCIDornudemice)forxenograf t models.
- Ethical approval obtained from the Institutional Animal Care and Use Committee (IACUC).

2. XenograftTumorModel:

- Subcutaneouslycancercelllinesinjectedby(A549,MCF-7,HCT116)intothe flanks of mice.
- Allowtumors to growtoapalpablesize(approximately100 mm^3).

3. TreatmentRegimen:

- Dividemiceintogroups(e.g.,vehiclecontrol,thioredoxinreductaseinhibitor treatment,combinationtreatmentswithantioxidants).

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

- Administer thioredoxin reductase inhibitors (e.g., Auranofin) intraperitoneally or orally at determined dosages and schedules.
- Monitortumor growthbymeasuringtumor sizewith caliperstwiceaweek.

4. ROS/RNSMeasurementinTumors:

- Excisetumorsattheendofthetreatment period.
- HomogenizetumortissuesandmeasureROS/RNSlevelsusingappropriate detection reagents (e.g., DCFDA, DAF-FM DA).
- Analyzefluorescenceintensityusingaplatereader orfluorescencemicroscope.

5. HistologicalAnalysis:

- Fix tumortissuesinformalinandembedinparaffin.
- Preparetissuesectionsandperformhematoxylinandeosin(H&E) staining.
- Assesstumor morphologyand necrosis under a microscope.

6. Immunohistochemistry(IHC):

- PerformIHContumorsectionsusingantibodiesagainstthioredoxinreductase, cleaved caspase-3, and markers of oxidative stress (e.g., 8-OHdG).
- Visualize and quantify staining using an appropriate detection system and image analysis software.

7. WesternBlotAnalysisofTumorTissues:

- Extractproteinsfromtumor tissues.
- PerformWesternblottingforthioredoxinreductase,cleavedPARP,cleavedcaspase-3, and β-actin.

8. StatisticalAnalysis:

- Performstatisticalanalysisusingsoftware(e.g., GraphPadPrism).
- Useappropriatetests (e.g.,Student'st-test,ANOVA)todeterminesignificance.
- Presentdataasmean ±SDand considerp <0.05asstatisticallysignificant.

OBJECTIVES

This research aims to clarify the therapeutic potential and better understand the mechanism of attack on thioredoxin reductase (TrxR) in the development of redox-regulated anticancer drugs. This general objective can be divided into the following

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

more specific objectives:

1. Recognize the molecular and cellular basis of cancer:

• Provide a comprehensive introduction to cancer biology, covering the molecular and genetic basis of the disease, epidemiological research, and historical context.

• Describe the characteristics that allow cancer cells to multiply, persist, and spread, explaining Hanahan and Weinberg's definition of the distinctive features of cancer.

2. Examine how oxidative stress affects cancer:

- Investigate the causes and effects of oxidative damage in biological contexts, focusing on the role of an imbalance between protective antioxidants and reactive oxygen species (ROS) in cancer initiation and spread.
- Examine how oxidative stress contributes to tumor heterogeneity, genomic instability, and treatment resistance.

3. Analyze redox balance in cancer cells:

• Elucidate the concept of redox homeostasis and its importance for preserving cell viability.

• Investigate how the increased generation of ROS and the alteration of antioxidant defenses, caused by the dysregulation of redox homeostasis in cancer cells, promote tumor development, survival, and metastasis.

Explore the Possible Benefits of Redox Homeostatic equilibrium Targeting:

- To examine current treatment approaches that work to modulate redox homeostasis, such as dual targeting, ROS-inducing, and antioxidant therapy.
- To evaluate these tactics' abilityto defeat resistance mechanisms and specifically cause the death of cancer cells.

3. Concentration onThioredoxinReductase(TrxR)andtheThioredoxin System:

- To give a thorough explanation of the thioredoxin system, covering thioredoxin's structure and function as well as TrxR's part in preserving cellular redox equilibrium.
- To investigate how TrxR activity is regulated and how it affects cancer cell survival, growth, and therapeutic resistance.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

4. EmphasizeTrxRInhibitors'TherapeuticPotential:

- Stay updated on the most recent advancements in the creation of TrxR inhibitors and the potential use of their applications in the battle against cancer.

- The primary objective of this study is to evaluate the potency of TrxR inhibitors by means of both experimental and clinical trials, specifically by concentrating on their ability to alter the redox state of tumor cells and thereby enhance the effectiveness of the standard cancer treatment.

7. Discuss the challenges and prospects of TrxR-targeted therapy: The use of TrxR as a therapeutic target for cancer still faces major obstacles: drug resistance, high toxicity, and the fact that its action is not limited solely to cancer cells. The first step is to promote the use of TrxR inhibitors in cancer treatment, outlining upcoming research and suggesting viable solutions to the aforementioned challenges. If these goals are achieved, current research will highlight the role of TrxR in cancer development and its potential for creating new, effective cancer drugs.

RESULTS

Mechanistic understanding of TrxR activity in cancer:

TrxR Expression and Activity: An exceptional critical review of the literature has highlighted the different levels of TrxR in different tumor tissues. In general, the increasing level of TrxR is the factor deciding the survival Medline and tumor growth kill. TrxR, being the most common characteristic of the tumors, is one of the death factors since it enables the tumor to withstand the oxygen deficiency stress. The metabolic activity of tumor cells gets support from a gradual process of their ionic species being oxidized and reduced, and they are thus either in the form of the electron acceptor or the electron donor and are therefore getting either ionic or non-ionic in form. Key Regulation Mechanisms of TrxR: The outcome of this research work is a major focus on the genome and post-translational modulation, and the redox interaction, which contribute to the critical control of TrxR production. Hence, it can be said that TrxR is one of the primary allies of the tumor cells in their battle against chemotherapy. Redox Signaling Pathways: The group of scientists examined a very complicated network picture in which the most essential interconnections between TrxR and cellular processes like apoptosis, DNA repair,

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

and gene regulation were clearly presented. The depletion of TrxR activity puts the tumor cells in a state that makes them vulnerable to oxidative damage and ultimately they die through apoptosis being the last cause of death.

1. The Potential Benefits of TrxR Inhibition Therapy:

Recent research has revealed that cancerous tumors are extremely intricate and have the most sophisticated capabilities to implement various oncogenic techniques to their own benefit to avoid dying and to continue moving. The prime factor among all these is the TrxR enzyme, which is involved in critical chemical reactions in the cell and in determining whether the cell will die or survive (death or survival) when stressed with toxins. Cancer status is characterized mainly by the control of oxidation-reduction reactions. Therefore, we should consider altering the chemical balance of tumor cells as one of the most effective ways to treat cancer. However, a major question remains: will changing the cells' reaction to this imbalance lead to their complete extinction? If so, it would undoubtedly be a very powerful and effective therapeutic strategy.

Significance And Implications:

1. Advancement in Cancer Biology:

Scientific investigation has revealed a plethora of intricate and extremely subtle mechanisms that the tumor cells rely on for survival and propagation. TrxR has been identified as a major contributory factor to the chemical equilibrium of the cell and this, in turn, is what ultimately decides the fate of the cell, death or life, when it is subjected to toxic agents. Redox Regulation in Cancer: The probe has again pointed out that chemical regulation is one of the leading factors in the process of cancer development. Therefore, the question is raised as to whether merely changing the cancer cells' sensitivity to this balance would really result in their complete extinction, which, in fact, would be an extremely powerful method of treatment.

2. Creation of Innovative Therapeutic Approaches:

Specific Therapy: TrxR being identified as a target for therapy paves the way for the development of tailored cancer treatments. One of the ways is through the use of TrxR inhibitors, which is a class of drugs that can selectively induce oxidative stress in cancer cells only. Combination Therapies: The results indicate that the

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

effectiveness of TrxR blockers might be increased if they are used in conjunction with other therapeutic methods. This strategy may lead to more precise and stronger therapy combinations for cancer patients in the future.

3. Clinical Consequences

Better Treatment Outcomes: The mix of TrxR inhibitors and the regular chemotherapy might produce more fulfilling results for the patients suffering from cancer. The explanation is the disappearance of the resistance patterns and the greater potency of the classical drugs, thus the survival rates and the patients' quality of life being improved. Precision Medicine: The research suggests that TrxR-directed therapy should be customized according to the patient's present drug schedule. The facilitation of treatment protocols that consider the redox condition of the tumor cells not only may result in more powerful treatments but also in fewer side effects.

Prospective Routes for Research

Mechanistic Studies: The TrxR regulation mechanism together with its association to varied tumors is still a topic of debate that calls for more investigation and research before definite conclusions can be made. Consequently, these studies will produce TrxR inhibitors, which will be more potent, highly selective, and versatile in the treatment according to the patient's unique molecular profile. Clinical Trials: The outcome of early-phase studies has been positive and has, on one hand, resulted in the demand for clinical trials to test the safety and effectiveness of TrxR inhibitors in the cancer patient population, on the other hand. Naturally, the medical community's acceptance of TrxR-targeted therapies will depend a lot on the results of such trials. Biomarker Development: The discovery of markers that reveal the redox state and TrxR activity will serve to not only patient selection but also to the monitoring of treatment response. What is more, such markers will be a key factor in deciding when the TrxR inhibitors should be given and in the assessment of the therapy's success.

CONCLUSION

Thyoredoxin Reductase (TrxR) enzyme is believed to be among the prime reasons of cancer and the current study aims to unravel its secrets and make a universal drug.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

As per the article, TrxR functions almost like a keeper of the ideal intracellular levels of the chemicals that are involved in the oxygen reactions for the cell. Such a scenario indirectly results in the lactation of the cancer cells and their facility to stand even the traditional treatments. TrxR is said to be overactive in various cancers to the point that it not only makes the cell live but also grow. TrxR reduces the cell's exposure to oxidative stress by picking the death, DNA repair, or even gene expression change of the cells as the outcome. It is suggested that TrxR inhibitors could be the agents that bring about the selective apoptosis of cancerous cells while allowing the logics of the non-infected ones to live on. The application of these kinds of agents along with radiotherapy or chemotherapy not only boosts the former's effectiveness against the latter but also simultaneously reduces the latter's risk of developing resistance. In addition, the research reaffirms TrxR's role in regulating the internal chemical composition of the cell as well as the characteristics of TrxR that make the cancer cell hard to get rid of. The study unravels the primary drivers of TrxR such as its transcriptional control, post-translational modifications, and the connections with other molecules that influence the cellular chemical equilibrium. The recognition of TrxR as a therapeutic target can not only facilitate the development of novel anti-cancer drugs but also contribute to the formulation of new cancer therapies.

REFERENCES

1. Junmin Zhang, Dongzhu Duan, Alsiddig Osama, and Jianguo Fang. Natural Molecules Targeting Thioredoxin System and Their Therapeutic Potential.Antioxidants & Redox Signaling. May 2021.1083-1107.
2. Costea T, Hudita A, Ciolac OA, Galateanu B, Ginghina O, Costache M, Ganea C, and Mocanu MM. Chemopreven- tion of colorectal cancer by dietary compounds. Int J Mol Sci 19: 3787, 2018
3. Cebula M, Schmidt EE, and Arner ESJ. TrxR1 as a potent regulator of the Nrf2- Keap1 response system. Antioxid Redox Signal 23: 823–853, 2015.
4. Zhang J, Li X, Han X, Liu R, and Fang J. Targeting the thioredoxin system for cancer therapy. Trends Pharmacol Sci 38: 794–808, 2017.
5. C.I.KobayashiandT.Suda,"Regulationofreactiveoxygenspeciesinstemcells and

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

cancer stem cells," Journal of Cellular Physiology, vol. 227, no. 2, pp. 421– 430, 2012.

6. E. Giannoni, F. Buricchi, G. Raugei, G. Ramponi, and P. Chiarugi, "Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependentcellgrowth,"*MolecularandCellularBiology*,vol.25,no.15, pp. 6391–6403, 2005
7. Zhang J, Duan D, Song ZL, Liu T, Hou Y, Fang J. Small molecules regulating reactiveoxygenspecieshomeostasisforcancertherapy.MedicinalResRev(2021) 41(1):342–94.
8. MahmoodDF,AbderrazakA,ElHadriK,SimmetT,andRouisM.Thethioredoxin systemas atherapeutictarget inhumanhealthanddisease. Antioxid Redox Signal 19: 1266–1303, 2013
9. Dixit D, Schmidt EE, and Arner ESJ. The A to Z of modulated cell patterning by mammalian thioredoxin reductases. Free Radic Biol Med 115: 484–496, 2018
10. Arner ESJ. Focus on mammalian thioredoxin reductases— important selenoproteins with versatile functions. Biochim Biophys Acta 1790: 495–526, 2009
11. Hornsveld M and Dansen TB. The hallmarks of cancer from a redox perspective. Antioxid Redox Signal 25: 300– 325, 2016
12. ReichHJ,HondalRJ.WhyNatureChoseSelenium.ACSChemBiol2016;11:82141.
13. WitteAB,AnestalK,JerremalmE,EhrssonH,Arner ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containinganticancercompounds.FreeRadicBiolMed2005;39:696-703.
14. Tonissen KF. Targeting the human thioredoxin system by diverse strategies to treat cancer and other pathologies. Recent Pat DNA Gene Seq 1: 164–175, 2007.
15. YoshiokaJ,SchreiterER,andLeeRT.Roleofthior-edoxinincellgrowththrough interactionswithsignalingmolecules.AntioxidRedoxSignal8:2143–2151,2006.
16. Zhu J-Y, Lou L-L, Guo Y-Q, Li W, Guo Y-H, Bao J-M,Tang G-H, Bu X-Z, and Yin S. Natural thioredoxin re- ductase inhibitors from Jatropha integerrima. RSC Adv 5: 47235–47243, 2015.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

17. LiuY,ZhaoY,WeiZ,TaoL,ShengX,WangS,ChenJ,RuanJ,LiuZ,CaoY, Shan Y, Wang A, Chen W, and LuY. Targeting thioredoxin system with an organosulfur compound, diallyl trisulfide (DATS), attenuates progres- sion andmetastasisoftriple-negativebreastcancer(TNBC).*CellPhysiolBiochem* 50: 1945–1963, 2018.
18. Dixit D,Sharma V, Ghosh S, Koul N, MishraPK, and Sen E. Manumycin inhibits STAT3, telomerase activity, and growthof gliomacells byelevating intracellular re- active oxygen species generation. Free Radic Biol Med 47: 364–374, 2009.
19. Li X, Fan XX, Jiang ZB, Loo WT, Yao XJ, Leung EL, Chow LW, and Liu L. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and acti- vating the EGFR proteasomal degradation pathway. Pharmacol Res 115: 45–55, 2017.
20. Li X, Hou Y, Meng X, Ge C, Ma H, Li J, and Fang J. Selective activation of a prodrugbythioredoxinreductaseprovidingastrategytotargetcancercells.Angew Chem Int Ed Engl 57: 6141–6145, 2018.
21. Li X, Zhang B, Yan C, Li J, Wang S, Wei X, Jiang X, Zhou P, and Fang J. A fast and specific fluorescent probe for thioredoxin reductase that works via disulphide bond cleavage. Nat Commun 10: 2745, 2019.
22. Liang W, Fernandes AP, Holmgren A, Li X, and Zhong L. Bacterial thioredoxin and thioredoxin reductase as medi- ators for epigallocatechin 3-gallate-induced antimicrobial action. FEBS J 283: 446–458, 2016.
23. HanX,ZhangJ,ShiD,WuY,LiuR,LiuT,XuJ,YaoX,andFangJ.Targeting thioredoxin reductase by ibrutinib promotes apoptosis of SMMC-7721 cells. J Pharmacol Exp Ther 369: 212–222, 2019.
24. Fritz-Wolf K, Jortzik E, Stumpf M, Preuss J, Iozef R, Rahlfs S, et al. Crystal structure of the Plasmodium falciparum thioredoxin reductase-thioredoxin complex. J Mol Biol 2013;425:3446-60.
25. She M, Yang H, Sun L, and Yeung SC. Redox control of manumycin A-induced apoptosis in anaplastic thyroid cancer cells: involvement of the xenobiotic apoptotic pathway. Cancer Biol Ther 5: 275–280, 2006.
26. Jakubikova J, Sedlak J, Bod'o J, and Bao Y. Effect of isothiocyanates on nuclear

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

accumulation of NF-kappaB, Nrf2, and thioredoxin in caco-2 cells. J Agric Food Chem 54: 1656–1662, 2006.

27. Chi Y, Zhan XK, Yu H, Xie GR, Wang ZZ, Xiao W, Wang YG, Xiong FX, Hu JF, Yang L, Cui CX, and Wang JW. An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors. Chin Med J (Engl) 126: 1642–1646, 2013
28. Holmgren A and Lu J. Thioredoxin and thioredoxin reduc- tase: current research with special reference to human dis- ease. Biochem Biophys Res Commun 396: 120–124, 2010.
29. Benhar M, Shytaj IL, Stamler JS, and Savarino A. Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J Clin Invest 126: 1630– 1639, 2016.
30. Powis G and Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. *Curr Opin Pharmacol* 7: 392– 397, 2007.
31. Arnér ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol. 2006;16(6):420-426.
32. Lu J, Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med. 2014;66:75-87.
33. Arner ES. Focus on mammalian thioredoxin reductases--important selenoproteins with versatile functions. Biochim Biophys Acta. 2009;1790(6):495-526.
34. Zhang J, Li X, Han X, Liu R, Fang J. Targeting the thioredoxin system for cancer therapy. Trends Pharmacol Sci. 2017;38(9):794-808.
35. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated
echanisms:aradicaltherapeuticapproach?NatRevDrugDiscov.2009;8(7):579- 591.
36. Harris IS, Treloar AE, Inoue S, et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 2015;27(2):211-222.
37. Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter,

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

system x(c)(-): cystine supplier and beyond. Amino Acids. 2012;42(1):231-246.

38. Tew KD. Redox in redux: emergent roles forthioredoxin reductasein mechanistic and therapeutic aspects of cancer. Oncogene. 2016;35(8):860-869.
39. GromerS,UrigS,BeckerK.Thethioredoxinsystem—fromsciencetoclinic.Med Res Rev. 2004;24(1):40-89.
40. Selenius M, Rundlöf AK, Olm E, Fernandes AP, Björnstedt M. Selenium and the selenoproteinthioredoxinreductaseintheprevention, treatmentanddiagnosticsof cancer. Antioxid Redox Signal. 2010;12(7):867-880.
41. Rigobello MP, Scutari G, Boscolo R, Bindoli A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br J Pharmacol. 2002;136(8):1162-1168.
42. Chew EH, Lu J, Bradshaw TD, Holmgren A. Mutation of the active site of thioredoxinreductasefromEscherichiacoliincombinationwithvariousflavonoids and dietary compounds. J Med Chem. 2008;51(15):4631-4633.
43. Kipp AP, Banning A, van Schothorst EM, et al. A novel role for selenium in oxidative stress and DNA damage repair: implications for cancer prevention. Mol Carcinog. 2009;48(6):442-450.
44. Gandin V, Fernandes AP, Rigobello MP, et al. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem Pharmacol. 2010;79(2):90-101.
45. Du Y, Zhang H, Lu J, Holmgren A. Thioredoxin 1 is inactivated due to oxidation inducedbyperoxiredoxinunderoxidativestressandreactivatedbytheglutaredoxin system. J Biol Chem. 2013;288(45):32241-32247.
46. RaningaPV,DiTrapaniG,VuckovicS,TonissenKF.TrxR1inhibitionovercomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-κB inhibition. Cell Cycle. 2016;15(5):559-572.
47. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. [PubMed] [Google Scholar] [Ref list]
48. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

2011;144:646–674. [PubMed] [Google Scholar] [Ref list]

49. Weinberg RA. Coming full circle-from endless complexity to simplicity and back again. Cell. 2014;157:267–271. [PubMed] [Google Scholar] [Ref list]
50. Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology. 2010;25:85–101. [PMC free article] [PubMed] [Google Scholar] [Ref list]
51. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389–396. [PubMed] [Google Scholar] [Ref list]
52. SteegPS.Tumormetastasis:mechanisticinsightsandclinicalchallenges.NatMed. 2006;12:895–904. [PubMed] [Google Scholar] [Ref list]
53. Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review Eur J Med Chem. 2015;97:55–74
54. Abreu IA, Cabelli DE. Superoxide dismutases – A review of the metal-associated mechanistic variations Biochim Biophys Acta. 2010;1804:263–74
55. Baker, A.F., Dragovich, T., Tate, W.R., Ramanathan, R.K., Roe, D.J., and Houghton, P.J. (2008). A phase I and pharmacokinetic study of the thioredoxin reductase inhibitor PX-12 in patients with advanced solid tumors. Clinical Cancer Research, 14(9), 3036-3044.
56. Berndt, C., Lillig, C.H., and Holmgren, A. (2012). Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. American Journal of Physiology-Heart and Circulatory Physiology, 302(6), H1227-H1239.
57. Boivin, B., Yang, M., and Tonks, N.K. (2010). Targeting the reversibly oxidized protein tyrosine phosphatase superfamily. Science Signaling, 3(137), mr2.
58. Brigelius-Flohé,R.,andMaiorino,M.(2013).Glutathioneperoxidases.Biochimica et Biophysica Acta (BBA)-General Subjects, 1830(5), 3289-3303.
59. Brookes, P.S., Yoon, Y., Robotham, J.L., Anders, M.W., and Sheu, S.S. (2004). Calcium, ATP, and ROS: a mitochondrial love-hate triangle. American Journal of Physiology-Cell Physiology, 287(4), C817-C833.
60. Carmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other diseases.

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

Nature, 407(6801), 249-257.

61. Chen, W., and Liu, Y. (2015). Reactive oxygen species in the regulation of autophagy. Autophagy, 5(4), 429-431.
62. Circu,M.L.,andAw,T.Y.(2010).Reactiveoxygenspecies,cellularredoxsystems, and apoptosis. Free Radical Biology and Medicine, 48(6), 749-762.
63. Conrad, M., and Sato, H. (2012). The oxidative stress-inducible cystine/glutamate antiporter,systemxc-:cystinesupplierandbeyond.AminoAcids,42(1),231-246.
64. Fan, C., Zheng, W., Fu, X., Li, X., Wong, Y.S., and Chen, T. (2014). Strategy to enhance the anticancer efficacy of selenium nanoparticles by targeting the tumor microenvironment. Biomaterials, 35(25), 6694-6703.
65. Finkel, T. (2011). Signal transduction by reactive oxygen species. Journal of Cell Biology, 194(1), 7-15.
66. Forman,H.J.,andZhang,H.(2001).Targetingoxidativestressindisease:promise and limitations of antioxidant therapy. Nature Reviews Drug Discovery, 1(1), 85- 95.
67. Gorrini, C., Harris, I.S., and Mak, T.W. (2013). Modulation of oxidative stress as an anticancer strategy. Nature Reviews Drug Discovery, 12(12), 931-947.
68. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell, 100(1), 57-70.
69. Hanahan,D.,andWeinberg,R.A.(2011).Hallmarksofcancer:thenextgeneration. Cell, 144(5), 646-674.
70. Holmgren, A., and Lu, J. (2010). Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochemical and Biophysical Research Communications, 396(1), 120-124.
71. Jones, D.P. (2006). Redefining oxidative stress. Antioxidants & Redox Signaling, 8(9-10), 1865-1879.
72. Klaunig, J.E., Kamendulis, L.M., and Hocevar, B.A. (2010). Oxidative stress and oxidative damage in carcinogenesis. Toxicologic Pathology, 38(1), 96-109.
73. Lambeth, J.D. (2004). NOX enzymes and the biology of reactive oxygen. Nature Reviews Immunology, 4(3), 181-189.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

74. Lu,J.,andHolmgren,A.(2014).Thethioredoxinantioxidantsystem.FreeRadical Biology and Medicine, 66, 75-87.

75. Lu,J.,Papp,L.V.,Fang,J.,Rodriguez-Nieto,S.,Zhivotovsky,B.,andHolmgren,

A. (2006). Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Research, 66(8), 4410-4418.

76. Mantel, C., Messina-Graham, S., Moh, A., Cooper, S., Hangoc, G., Fu, X., and Broxmeyer, H.E. (2010). Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype. Blood, The Journal of the American Society of Hematology, 115(19), 4026-4037.

77. Maraldi, T., Angeloni, C., Giannoni, E., Sell, C., and Mangraviti, S. (2019). Reactive oxygen species in tumor angiogenesis. Molecular and Cellular Biology, 39(7), e00275-18.

78. Matés,J.M.,Segura,J.A.,Alonso,F.J.,andMárquez,J.(2012).Intracellularredox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Archives of Toxicology, 86(10), 1717-1738.

79. Miller, E., Morel, A., and Saso, L. (2020). The role of oxidative stress in the pathogenesis and therapeutic strategies in chronic lymphocytic leukemia (CLL). Free Radical Biology and Medicine, 147, 93-106.

80. Mitsui, A., Hamuro, J., Nakamura, H., Kondo, N., Hirabayashi, Y., Ishizaki-Koizumi, S., and Yodoi, J. (2002). Overexpression of thioredoxin in transgenic mice accelerates skin wound healing. FEBS Letters, 535(1-3), 161-164.

81. Muller, F.L., Lustgarten, M.S., Jang, Y., Richardson, A., and Van Remmen, H. (2007). Trends in oxidative aging theories. Free Radical Biology and Medicine, 43(4), 477-503.

82. Nordberg, J., and Arnér, E.S. (2001). Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radical Biology and Medicine, 31(11), 1287-1312.

83. Pisoschi, A.M., and Pop, A. (2015). The role of antioxidants in the chemistry of oxidative stress: a review. European Journal of Medicinal Chemistry, 97, 55-74.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

84. Pompella,A.,Visvikis,A.,Paolicchi,A.,DeTata,V.,andCasini,A.F.(2003).The changing faces of glutathione, a cellular protagonist. Biochemical Pharmacology, 66(8), 1499-1503.
85. Powell, S.R. (2000). The antioxidant properties of zinc. Journal of Nutrition, 130(5S), 1447S-1454S.
86. Rhee, S.G. (2006). Cell signaling. H2O2, a necessary evil for cell signaling. Science, 312(5782), 1882-1883.
87. Rigobello, M.P., and Bindoli, A. (2010). Mitochondrial thioredoxin reductase: a new player in pathophysiology. Molecular Aspects of Medicine, 31(1), 75-82.
88. Schieber, M., and Chandel, N.S. (2014). ROS function in redox signaling and oxidative stress. Current Biology, 24(10), R453-R462.
89. Steeg,P.S.(2006).Tumormetastasis:mechanisticinsightsandclinicalchallenges. Nature Medicine, 12(8), 895-904.
90. Valko, M., Rhodes, C.J., Moncol, J., Izakovic, M., and Mazur, M. (2006). Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chemico- Biological Interactions, 160(1), 1-40.
91. Watson,J.(2013).Oxidants,antioxidants,andthecurrentincurabilityofmetastatic cancers. Open Biology, 3(1), 120144.
92. Winterbourn,C.C.,and Hampton,M.B. (2008). Thiolchemistryand specificityin redox signaling. Free Radical Biology and Medicine, 45(5), 549-561.
93. Wouters, B.G., and Koritzinsky, M. (2008). Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nature Reviews Cancer, 8(11), 851- 864.
94. Yan, L., and Lee, H.J. (2010). Redox imbalance stress in cancer progression. Redox Biology, 1(1), 35-38.
95. Yang,H.,andTonge,P.J.(2012).Drugresistance:therolesofmutationandgene amplification. Chemical Biology, 19(1), 60-71.
96. Zhang,D.X.,andGutterman,D.D.(2007).Mitochondrialreactiveoxygenspecies-mediatedsignalinginendothelialcells.AmericanJournalofPhysiology-Heartand Circulatory Physiology, 292(5), H2023-H2031.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 4, Issue 1 (2026)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

97. Zhang,W.,andLiu,H.T.(2002).MAPKsignalpathwaysintheregulationofcell proliferation in mammalian cells. Cell Research, 12(1), 9-18.

98. Zhao,Y.,andRobbins,M.E.(2009).Inflammationandchronicoxidativestressin radiation-induced late normal tissue injury: therapeutic implications. Current Medicinal Chemistry, 16(2), 130-143.

99. Zhou, T., Prather, E.R., Garrison, D.E., Zuo, L., and Guo, Z. (2019). Antioxidant characterization of the p53 and HIF pathways in cancer: a review. Frontiers in Oncology, 9, 1348.

100. Zhu, J., and Thompson, C.B. (2019). Metabolic regulation of cell growth and proliferation. Nature Reviews Molecular Cell Biology, 20(7), 436-450.

101. Zou, M.H., Hou, X.Y., and Shi, C.M. (2010). Oxidative stress-activated JNK signaling: a novel pathway involved in cell apoptosis. Journal of Biomedical Science, 17(1), 12.